Loading...

Epigenomics AG

ECX.DE•XETRA
Healthcare
Medical - Diagnostics & Research
€0.70
€-0.09(-11.17%)

Epigenomics AG (ECX.DE) Stock Overview

Explore Epigenomics AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.1/100

Key Financials

Market Cap612.6K
P/E Ratio-0.24
EPS (TTM)$-19.55
ROE-0.74%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.39

ECX.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Epigenomics AG (ECX.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.39.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.24 and a market capitalization of 612.6K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ECX.DEStats details for ECX.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ECX.DEAnalyst Recommendations details for ECX.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

CEO

Noel Thomas Doheny

Employees

36

Headquarters

Geneststrasse 5, Berlin

Founded

2004

Frequently Asked Questions

;